MENU
+Compare
ASND
Stock ticker: NASDAQ
AS OF
May 14, 04:59 PM (EDT)
Price
$157.21
Change
-$4.31 (-2.67%)
Capitalization
9.75B

ASND Ascendis Pharma A/S Forecast, Technical & Fundamental Analysis

Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients... Show more

Industry: #Biotechnology
ASND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ASND with price predictions
May 13, 2025

ASND in upward trend: price may jump up because it broke its lower Bollinger Band on May 09, 2025

ASND may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 41 cases where ASND's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

ASND moved above its 50-day moving average on May 13, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ASND crossed bullishly above the 50-day moving average on April 22, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ASND advanced for three days, in of 276 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 116 cases where ASND Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ASND moved out of overbought territory on May 01, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on May 08, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ASND as a result. In of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ASND turned negative on May 08, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ASND declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ASND’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ASND’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (14.386). P/E Ratio (0.000) is within average values for comparable stocks, (64.760). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.146). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (22.883) is also within normal values, averaging (254.479).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
ASND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ASND is expected to report earnings to fall 13.92% to -136 cents per share on September 09

Ascendis Pharma A/S ASND Stock Earnings Reports
Q2'25
Est.
$-1.36
Q1'25
Missed
by $0.11
Q4'24
Beat
by $0.34
Q3'24
Missed
by $0.18
Q2'24
Missed
by $0.45
The last earnings report on May 01 showed earnings per share of -158 cents, missing the estimate of -147 cents. With 75.41K shares outstanding, the current market capitalization sits at 9.75B.
A.I. Advisor
published General Information

General Information

a developer of drug candidates

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
Tuborg Boulevard 12
Phone
+45 70222244
Employees
879
Web
https://www.ascendispharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA334.0715.69
+4.93%
Tesla
BTC.X104169.8100001356.851600
+1.32%
Bitcoin cryptocurrency
GME28.390.34
+1.21%
GameStop Corp
AAPL212.932.14
+1.02%
Apple
SPY586.843.85
+0.66%
SPDR® S&P 500® ETF

ASND and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ASND has been loosely correlated with NUVL. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ASND jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ASND
1D Price
Change %
ASND100%
+4.59%
NUVL - ASND
37%
Loosely correlated
-3.00%
INSM - ASND
32%
Poorly correlated
-3.01%
BMRN - ASND
31%
Poorly correlated
-2.59%
AVIR - ASND
31%
Poorly correlated
-11.15%
TECH - ASND
31%
Poorly correlated
-4.25%
More